Tigecycline + ampicillin-sulbactam
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Skin Diseases, Bacterial
Conditions
Skin Diseases, Bacterial
Trial Timeline
Sep 1, 2006 → Sep 1, 2008
NCT ID
NCT00368537About Tigecycline + ampicillin-sulbactam
Tigecycline + ampicillin-sulbactam is a approved stage product being developed by Pfizer for Skin Diseases, Bacterial. The current trial status is completed. This product is registered under clinical trial identifier NCT00368537. Target conditions include Skin Diseases, Bacterial.
What happened to similar drugs?
6 of 20 similar drugs in Skin Diseases, Bacterial were approved
Approved (6) Terminated (7) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00368537 | Approved | Completed |
Competing Products
20 competing products in Skin Diseases, Bacterial